Omeros corporation reports narsoplimab treatment results in critically ill covid-19 patients in i-spy covid trial

Seattle--(business wire)--omeros corporation (nasdaq: omer) today reported results from the narsoplimab arm of the i-spy covid trial, sponsored by quantum leap healthcare collaborative (qlhc). analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with covid-19 reduces the mortality risk (hazard ratio [hr]=0.81, with probability [hr
OMER Ratings Summary
OMER Quant Ranking